MedTrace Logo

A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

NCT07737600 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2026-08-04

No results posted yet for this study

Summary

This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.

Conditions

  • Advanced Colorectal Cancer

Interventions

DRUG

MRG007

MRG007 will be administrated as specified in the protocol.

DRUG

5-Fluorouracil / Leucovorin Calcium

5-Fluorouracil / Leucovorin Calcium will be administrated as specified in the protocol.

DRUG

Bevacizumab

Bevacizumab will be administrated as specified in the protocol.

DRUG

Oxaliplatin

Oxaliplatin will be administrated as specified in the protocol.

DRUG

PD-1/VEGF antibody

PD-1/VEGF antibody will be administrated as specified in the protocol.

DRUG

Capecitabine

Capecitabine will be administrated as specified in the protocol.

Sponsors & Collaborators

  • Lepu Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07737600 on ClinicalTrials.gov